ストックスクリーナーアプリを入手
24.09
0.08%
-0.02
アフターアワーズ：
24.09
前日終値:
$24.11
開ける：
$24.2
24時間の取引高:
333.27K
Relative Volume:
0.45
時価総額：
$1.17B
収益：
$458.69M
当期純損益:
$11.68M
株価収益率:
100.29
EPS:
0.2402
ネットキャッシュフロー:
$14.58M
1週間 パフォーマンス:
+0.50%
1か月 パフォーマンス:
+17.68%
6か月 パフォーマンス:
-45.68%
1年 パフォーマンス:
-26.01%
1日の値動き範囲:
$23.66
$24.23
1週間の範囲:
$23.20
$25.38
52週間の値動き範囲:
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
Compare AORT vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
24.09 | 1.17B | 458.69M | 11.68M | 14.58M | 0.2402 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2025-08-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2025-06-17 | 開始されました | Canaccord Genuity | Buy |
| 2024-10-23 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-27 | 繰り返されました | Lake Street | Buy |
| 2022-08-08 | 開始されました | Lake Street | Buy |
| 2022-03-03 | 開始されました | Stifel | Buy |
すべてを表示
Artivion Inc (AORT) 最新ニュース
What Boosted Artivion (NYSE:AORT) Following FDA PMA Approval? - Kalkine Media
Artivion (AORT) Is Up 10.1% After Full FDA PMA Approval for AMDS Aortic Device - simplywall.st
Artivion seeks to tap $150 million US market opportunity with FDA approval - MSN
Artivion stock gets FDA approval for NEXUS stent graft system By Investing.com - Investing.com India
Artivion (AORT) Stock Forum and Discussion - Moomoo
AORTArtivion Inc Options - Finviz
Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth - MSN
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device - Yahoo Finance
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion (NYSE:AORT) - Seeking Alpha
Artivion stock rises after FDA approves AMDS device - Investing.com
Enterprise value to revenue forward of Artivion, Inc. – SWB:CYL - TradingView
Canaccord reiterates Artivion stock rating on FDA approval By Investing.com - Investing.com South Africa
Artivion (AORT) Secures FDA Approval for AMDS Hybrid Prosthesis - GuruFocus
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval - Benzinga
Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis - simplywall.st
Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections - grafa.com
Canaccord reiterates Artivion stock rating on FDA approval - Investing.com
Artivion Shares Rise After FDA Approves AMDS Aortic Device - TradingPedia
Artivion Wins FDA Nod for AMDS Hybrid Prosthesis - Medical Product Outsourcing
Artivion stock rises after FDA approves AMDS device By Investing.com - Investing.com Canada
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Artivion's Hybrid Prosthesis Device Gets FDA Premarket Approval; Shares Up Pre-Bell - Moomoo
Artivion receives FDA approval for aortic dissection device By Investing.com - Investing.com South Africa
Artivion receives FDA approval for aortic dissection device - Investing.com
Artivion, Inc.(NYSE: AORT) dropped from Russell 2000 Value Benchmark - marketscreener.com
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis - PR Newswire
Artivion, Inc.(NYSE: AORT) dropped from Russell 3000E Index - marketscreener.com
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Index - marketscreener.com
Artivion, Inc.(NYSE: AORT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Artivion, Inc.(NYSE: AORT) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to earnings forward of Artivion, Inc. – NYSE:AORT - TradingView
Enterprise value to EBITDA forward of Artivion, Inc. – SWB:CYL - TradingView
Price to sales forward of Artivion, Inc. – SWB:CYL - TradingView
Artivion, Inc.(NYSE: AORT) dropped from Russell 3000E Value Benchmark - marketscreener.com
Artivion, Inc. Actuals & Estimates (NYSE:AORT) - TradingView
AORT Forecast — Price Target — Prediction for 2027 - TradingView
AORT Q1 2026 Earnings: EPS Misses Estimates, Yet Stock Gains 2.86% on Operational ResilienceEarnings Analysis - dars.gov.et
Artivion Inc (AORT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $44 - Moomoo
At US$21.19, Is It Time To Put Artivion, Inc. (NYSE:AORT) On Your Watch List? - Moomoo
Q1 2026 Artivion Inc Earnings Call Transcript - GuruFocus
Delray Medical Center is First Hospital in Palm Beach County to Perform Procedure Using AMDS™ Hybrid Prothesis Developed by Artivion Inc. - Florida Hospital News and Healthcare Report
Artivion Inc (AORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Artivion Inc (AORT) Institutional Confidence - TradingKey
Artivion Inc (AORT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Artivion Inc (AORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AORT Q1 2026 Earnings: EPS Misses Estimates by 40%, Shares DeclineRevenue Report - dars.gov.et
Artivion Inc (AORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Artivion Inc (AORT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Artivion Inc (AORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Artivion Inc (AORT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Artivion Inc (AORT) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
大文字化:
|
ボリューム (24 時間):